1. Home
  2. TRX vs ASMB Comparison

TRX vs ASMB Comparison

Compare TRX & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TRX Gold Corporation

TRX

TRX Gold Corporation

N/A

Current Price

$0.96

Market Cap

228.9M

Sector

N/A

ML Signal

N/A

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$36.20

Market Cap

553.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRX
ASMB
Founded
1990
2005
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
228.9M
553.6M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
TRX
ASMB
Price
$0.96
$36.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$1.25
$43.40
AVG Volume (30 Days)
1.6M
115.0K
Earning Date
01-13-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.00
N/A
Revenue
$57,613,000.00
$37,191,000.00
Revenue This Year
$28.16
$42.01
Revenue Next Year
N/A
N/A
P/E Ratio
$376.20
N/A
Revenue Growth
39.98
31.30
52 Week Low
$0.27
$7.75
52 Week High
$0.91
$39.71

Technical Indicators

Market Signals
Indicator
TRX
ASMB
Relative Strength Index (RSI) 73.32 57.14
Support Level $0.84 $32.25
Resistance Level $0.89 $36.92
Average True Range (ATR) 0.05 1.85
MACD 0.01 -0.28
Stochastic Oscillator 96.31 56.68

Price Performance

Historical Comparison
TRX
ASMB

About TRX TRX Gold Corporation

TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: